VRTX Earnings & Financial Statements
Vertex Pharmaceuticals Incorporated
$498.50
+$13.28(+2.74%)
51
Overall
60
Value
30
Tech
63
Quality
Market Cap
$122.98B
Volume
2.06M
52W Range
$402.58 - $560.25
Target Price
$572.86
VRTX earnings and financial statements: Vertex Pharmaceuticals Incorporated's income statement, balance sheet and cash flow statement, annual and quarterly.
VRTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Cost of revenue | $1.65B | $1.53B | $1.26B | $1.08B | $904.20M |
| Operating income | $4.17B | -$232.90M | $3.83B | $4.31B | $2.78B |
| EBITDA | $4.87B | $486.30M | $4.61B | $4.44B | $2.92B |
| Net income | $3.95B | -$535.60M | $3.62B | $3.32B | $2.34B |
| EPS (diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B |
| Shareholders’ equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B |
| Cash and equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.80B |
| Long-term debt | $1.85B | $1.54B | $724.70M | $810.30M | $887.20M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $3.63B | -$492.60M | $3.54B | $4.13B | $2.64B |
| Capital expenditure | -$437.60M | -$297.70M | -$200.40M | -$204.70M | -$235.00M |
| Free cash flow | $3.19B | -$790.30M | $3.34B | $3.93B | $2.41B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRTX | $498.50 | +2.7% | 2.06M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Vertex Pharmaceuticals Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW